These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2651492)

  • 1. Subjective profile of phenylpropanolamine: absence of stimulant or euphorigenic effects at recommended dose levels.
    Morgan JP; Funderburk FR; Blackburn GL; Noble R
    J Clin Psychopharmacol; 1989 Feb; 9(1):33-8. PubMed ID: 2651492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenylpropanolamine: reinforcing and subjective effects in normal human volunteers.
    Chait LD; Uhlenhuth EH; Johanson CE
    Psychopharmacology (Berl); 1988; 96(2):212-7. PubMed ID: 3148148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenylpropanolamine: a controversy unresolved.
    Miller LG
    J Clin Psychopharmacol; 1989 Feb; 9(1):1-3. PubMed ID: 2708553
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind clinical evaluation of the anorectic activity of phenylpropanolamine versus placebo.
    Greenway F
    Clin Ther; 1989; 11(5):584-9. PubMed ID: 2680083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reinforcing and subjective effects of several anorectics in normal human volunteers.
    Chait LD; Uhlenhuth EH; Johanson CE
    J Pharmacol Exp Ther; 1987 Sep; 242(3):777-83. PubMed ID: 3656112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of phenylpropanolamine in the management of moderate obesity.
    Schteingart DE
    Int J Obes Relat Metab Disord; 1992 Jul; 16(7):487-93. PubMed ID: 1323545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled clinical trial of the cardiovascular and psychological effects of phenylpropanolamine and caffeine.
    Noble R
    Drug Intell Clin Pharm; 1988 Apr; 22(4):296-9. PubMed ID: 3286173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers.
    Brauer LH; de Wit H
    Biol Psychiatry; 1996 Jan; 39(1):26-32. PubMed ID: 8719123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse liability assessment of atomoxetine in a drug-abusing population.
    Jasinski DR; Faries DE; Moore RJ; Schuh LM; Allen AJ
    Drug Alcohol Depend; 2008 May; 95(1-2):140-6. PubMed ID: 18328639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
    Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
    Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reinforcing and subjective effects of the volatile anesthetic, sevoflurane.
    Walker DJ; Beckman NJ; Zacny JP
    Drug Alcohol Depend; 2004 Nov; 76(2):191-201. PubMed ID: 15488343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of conjugated linoleic acid supplementation after weight loss on appetite and food intake in overweight subjects.
    Kamphuis MM; Lejeune MP; Saris WH; Westerterp-Plantenga MS
    Eur J Clin Nutr; 2003 Oct; 57(10):1268-74. PubMed ID: 14506488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
    Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
    J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.
    Zacny JP
    Psychopharmacology (Berl); 2003 Jan; 165(2):146-56. PubMed ID: 12404072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological, subjective and performance effects of pseudoephedrine and phenylpropanolamine during endurance running exercise.
    Chester N; Reilly T; Mottram DR
    Int J Sports Med; 2003 Jan; 24(1):3-8. PubMed ID: 12582945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral and neurochemical evaluation of phenylpropanolamine.
    Woolverton WL; Johanson CE; de la Garza R; Ellis S; Seiden LS; Schuster CR
    J Pharmacol Exp Ther; 1986 Jun; 237(3):926-30. PubMed ID: 3712285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual differences in the biphasic effects of ethanol.
    Holdstock L; de Wit H
    Alcohol Clin Exp Res; 1998 Dec; 22(9):1903-11. PubMed ID: 9884132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations of phenylpropanolamine and associated effects on blood pressure in normotensive subjects: a pilot-study.
    Dowse R; Scherzinger SS; Kanfer I
    Int J Clin Pharmacol Ther Toxicol; 1990 May; 28(5):205-10. PubMed ID: 2194987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenylpropanolamine: effects on subjective and cardiovascular variables at recommended over-the-counter dose levels.
    Liebson I; Bigelow G; Griffiths RR; Funderburk FR
    J Clin Pharmacol; 1987 Sep; 27(9):685-93. PubMed ID: 3680599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.